Once viewed as low risk compared to small molecule production, bio sites are now operating 15K+ bioreactors, vast solvent systems, and steam infrastructure once unthinkable in biologics. And yet, many sites still fall outside of formal process safety rigor.

This panel tackles the growing disconnect between perceived and actual risk in modern biopharma, and how organisations are responding by applying process safety standards, KPIs, and culture to these “new old risks”.

• When is a biologics site no longer a “low risk” facility? Learn how to close the gap between infrastructure scale and safety oversight
• Applying PSM selectively: hazard-based vs blanket standards and how do different companies approach biopharma site PSM adoption?
• How KPIs mislead: lagging vs leading, and what’s actually useful, are we measuring the wrong things? Explore how other firms are redefining KPIs that reflect current realities, not just historical assumptions
• Identify which process safety elements are essential to modern biologics sites, even if you are not Seveso